Nuvalent, Inc. SEC Filings

Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported option exercises and sales on September 29-30, 2025. She acquired 7,588 shares on 09/29/2025 and 20,000 shares on 09/30/2025 by exercising stock options with an exercise price of $6.89 per share. Those exercises increased the number of shares underlying her options as reported in Table II to 79,638 and then to 59,638 following the reported activity.

Concurrently, Balcom sold the same numbers of Class A common shares: 7,588 shares on 09/29/2025 at a weighted average price of $85.01 (sales ranged $85.00–$85.05) and 20,000 shares on 09/30/2025 at a weighted average price reported at $85.06 (sales ranged $85.00–$85.37). After these transactions, the Form 4 shows 61,734 shares of Class A common stock beneficially owned.

Nuvalent insider transactions on 09/29/2025: Darlene Noci, Chief Development Officer, executed transactions under a Rule 10b5-1 plan adopted on November 18, 2024. She exercised a stock option to acquire 4,000 shares at an exercise price of $27.85 and contemporaneously sold 4,000 Class A common shares in multiple block sales at weighted average prices ranging from $81.39 to $84.92 across several lots.

Following these transactions the Form 4 reports 48,034 shares of Class A common stock beneficially owned and 4,000 shares subject to the option exercised, with the filing also showing 126,329 derivative securities beneficially owned following the reported transactions. The reporting attorney-in-fact signed the form on 10/01/2025.

Nuvalent, Inc. (NUVL) insider filing reports a proposed sale of 12,000 Class A Common shares through J.P. Morgan Securities on NASDAQ with an aggregate market value of $975,600. The shares were acquired and are to be sold on 09/29/2025 following a stock option exercise, with payment in cash. The filing identifies the selling person as Darlene Noci, who sold 4,000 shares on 07/30/2025 for $321,460 and 4,000 shares on 08/25/2025 for $298,494 during the prior three months. The filing also discloses 66,669,583 shares outstanding. No additional narrative, relationship to issuer, or trading-plan dates are provided in the notice.

Nuvalent, Inc. (ticker: NUVL) filed a Form 144 reporting a proposed sale of 60,000 shares of Class A common stock through J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value of $4,878,000 and an approximate sale date of 09/29/2025. The securities were acquired on 09/29/2025 through a stock option exercise and paid for in cash. The filing discloses two prior small sales by the same person in July 2025 totaling 20,000 shares for gross proceeds of $1,695,473. The filer certifies no undisclosed material adverse information.

Nuvalent, Inc. (NUVL) insider Form 4: James R. Porter, President and CEO and a director, reported transactions on 09/15/2025 effected under a Rule 10b5-1 trading plan. He acquired a stock option for 27,000 shares at an exercise price of $18.93 and simultaneously sold 27,000 shares in three tranches: 8,823 shares at a weighted average price of $78.42, 16,080 shares at $79.30, and 2,097 shares at $80.12. After these transactions the reporting person beneficially owned 249,062 shares of Class A common stock and held options covering 27,000 shares (report shows 249,400 derivative securities beneficially owned following the transactions). The filing was signed by attorney-in-fact Nathan McConarty on 09/17/2025.

Form 144 notice shows an insider sale filing for Nuvalent, Inc. (NUVL). The filer intends to sell 6,158 common shares through Morgan Stanley Smith Barney on the NASDAQ with an aggregate market value of $484,819.34. Those 6,158 shares were acquired the same day (09/10/2025) by exercising stock options and paid for in cash. The filing reports that 23,945 shares were sold over the prior three months under a mix of 10b5-1 plans and direct sales, generating total gross proceeds of $1,888,286.34. The seller identified in the filing is Henry E. Pelish. The form includes the standard signature representation that the seller is not aware of any undisclosed material adverse information.

Nuvalent, Inc. (NUVL) Form 4: Henry E. Pelish, the company’s Chief Scientific Officer, reported transactions dated 08/29/2025 that increased his direct holdings. The filing shows two non-derivative additions of 2,007 and 3,000 shares of Class A common stock at reported prices of $0.87 and $1.08, raising his beneficial ownership from 62,963 to 65,963 shares. Corresponding derivative entries show stock options for 2,007 shares exercisable through 12/15/2030 and 3,000 shares exercisable through 02/16/2031. The filer discloses the underlying option shares are fully vested. The submission is signed via attorney-in-fact Nathan N. McConarty on 09/03/2025.

Nuvalent insider transactions by Chief Development Officer Darlene Noci: The filing shows an option exercise and contemporaneous open-market sales done under a Rule 10b5-1 plan. The reporting person exercised a stock option to acquire 4,000 shares at $27.85 on 08/25/2025. On the same date she sold a total of 4,000 Class A shares in multiple transactions at weighted-average prices of $73.96, $74.93, and $75.63, reducing her direct Class A holdings from 52,034 to 48,034 shares. The Form 4 notes the 10b5-1 trading plan was adopted on November 18, 2024, and the reporting person will provide transaction-level sale prices on request.